Description

Trilostec Tablets

Trilostane Tablets for dogs

Reliable trilostane therapy for confident, long-term control of Cushing’s disease.
Cushing’s meets care. Care meets confidence.

Manufactured/Marketed by: PANAV BIO-TECH PVT. LTD.

Country of Origin: India.

Dosage form: Chewable, flavoured & divisible tablets.

Presentation:

40 mg tablets; 60 Tablets Box.

Ingredients & Composition

Trilostane (Active): 40 mg per uncoated tablet

Excipients: q.s.

Description / Action

Trilostec Tablets for dogs contains Trilostane for management of Cushing’s syndrome (hyperadrenocorticism). Divisible, flavoured tablets for tailored dosing under veterinary supervision.

Trilostec Tablets contains trilostane, a selective and reversible inhibitor of adrenal steroidogenesis that reduces excessive cortisol production. It is indicated for canine hyperadrenocorticism and is described in the supplied material as effective in both pituitary-dependent (PDH) and adrenal-dependent (ADH) forms.

Class: Adrenal enzyme inhibitor / antiadrenal preparation.

Indication / Uses

Canine hyperadrenocorticism (Cushing’s syndrome)

Pituitary-dependent hyperadrenocorticism (PDH)

Adrenal-dependent hyperadrenocorticism (ADH)

Helps reduce excessive cortisol production.

Dosage and administration

Starting dose: 2 mg/kg body weight once daily with food.

Dose should be titrated according to clinical response and monitoring. The 40 mg tablet incorporates Click-Tab divisible technology, allowing division into ½ = 20 mg and ¼ = 10 mg for tailored dosing and gradual dose titration.

Use the lowest effective dose to control clinical signs.

Monitoring: The supplied material recommends ACTH stimulation testing before treatment and subsequently at Day 10, Week 4, Week 12 and every 3 months, with monitoring after dose adjustments.

Overdose / Side effects / Contraindications / Warnings

Excessive suppression may result in iatrogenic hypoadrenocorticism, with lethargy, anorexia, vomiting, diarrhoea, weakness or collapse.

Rare adverse effects include ataxia, hypersalivation, bloating, muscle tremors and skin changes; adrenal necrosis and sudden death have been reported rarely.

Do not use in dogs with primary hepatic disease and/or renal insufficiency, known hypersensitivity, or in dogs weighing less than 3 kg according to the Vetoryl SPC.

Use caution in dogs with pre-existing anaemia and monitor liver enzymes, electrolytes, urea and creatinine.

Concurrent use with potassium-sparing diuretics or ACE inhibitors requires veterinary risk-benefit assessment because of the risk of hyperkalaemia.

Pharmaceutical precautions / Instructions

For use in dogs only.

Administer orally with food.

Treatment should be under veterinary supervision with regular clinical and hormonal monitoring.

Store in the original package and protect from light.

Safety: Age / Pregnancy / Withdrawal

Pregnancy/Lactation: Do not use in pregnant or lactating bitches or animals intended for breeding.

Withdrawal period: Not applicable.

Long-term therapy generally requires regular monitoring and dose adjustment.

Substitute: Vetoryl Tablets